Apimeds Pharmaceuticals US, Inc. (APUS) Stock Statistics & Valuation Metrics

Apimeds Pharmaceuticals US, Inc. has a market cap or net worth of $9.76M. The enterprise value is $10.20M.

Apimeds Pharmaceuticals US, Inc. has 15,091,177 shares outstanding. The number of shares has decreased by -2.65% in one year.

Apimeds Pharmaceuticals US, Inc.’s return on equity (ROE) is -0.04 and return on invested capital (ROIC) is -7.39%.

The current PE Ratio of Apimeds Pharmaceuticals US, Inc. is ―. Apimeds Pharmaceuticals US, Inc.’s PEG ratio is 0.06.

In the last 12 months, Apimeds Pharmaceuticals US, Inc. had revenue of 0.00 and earned -6.00M in profits. Earnings per share was -0.55.

In the last 12 months, operating cash flow was -11.05M and capital expenditures -66.73K, giving a free cash flow of -11.11M billion.

Apimeds Pharmaceuticals US, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Apimeds Pharmaceuticals US, Inc. upcoming earnings date is ―, ―.

Apimeds Pharmaceuticals US, Inc. as a current ratio of 1.31, with Debt / Equity ratio of 7.54%

In the past 12 months, Apimeds Pharmaceuticals US, Inc. has paid 0.00 in taxes.

Apimeds Pharmaceuticals US, Inc. EV to EBITDA ratio is -4.20, with an EV/FCF ratio of -2.67.

Apimeds Pharmaceuticals US, Inc. has $2.48M in cash and marketable securities with $9.53M in debt, giving a net cash position of -$7.05M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Apimeds Pharmaceuticals US, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―